William C. Zamboni
Department of Pharmaceutical Sciences
School of Pharmacy
University of Pittsburgh
Pittsburgh
USA
Name/email consistency: high
- Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. Zamboni, W.C., Strychor, S., Joseph, E., Parise, R.A., Egorin, M.J., Eiseman, J.L. Cancer Chemother. Pharmacol. (2008)
- Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice. Zamboni, W.C., Jung, L.L., Strychor, S., Joseph, E., Zamboni, B.A., Fetterman, S.A., Sidone, B.J., Burke, T.G., Curran, D.P., Eiseman, J.L. Invest. New. Drugs (2008)
- Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Zamboni, W.C., Strychor, S., Joseph, E., Walsh, D.R., Zamboni, B.A., Parise, R.A., Tonda, M.E., Yu, N.Y., Engbers, C., Eiseman, J.L. Clin. Cancer Res. (2007)
- Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Zamboni, W.C., Ramanathan, R.K., McLeod, H.L., Mani, S., Potter, D.M., Strychor, S., Maruca, L.J., King, C.R., Jung, L.L., Parise, R.A., Egorin, M.J., Davis, T.A., Marsh, S. Invest. New. Drugs (2006)
- Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts. Zamboni, W.C., Jung, L.L., Egorin, M.J., Hamburger, D.R., Joseph, E., Jin, R., Strychor, S., Ramanathan, R.K., Eiseman, J.L. Clin. Cancer Res. (2005)
- Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Zamboni, W.C., Gervais, A.C., Egorin, M.J., Schellens, J.H., Zuhowski, E.G., Pluim, D., Joseph, E., Hamburger, D.R., Working, P.K., Colbern, G., Tonda, M.E., Potter, D.M., Eiseman, J.L. Cancer Chemother. Pharmacol. (2004)
- Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Zamboni, W.C., Jung, L.L., Egorin, M.J., Potter, D.M., Friedland, D.M., Belani, C.P., Agarwala, S.S., Wong, M.M., Fakih, M., Trump, D.L., Jin, R., Strychor, S., Vozniak, M., Troetschel, M., Ramanathan, R.K. Clin. Cancer Res. (2004)
- Pharmacokinetics of pegfilgrastim. Zamboni, W.C. Pharmacotherapy (2003)
- An overview of the pharmacokinetic disposition of darbepoetin alfa. Zamboni, W.C., Stewart, C.E. Pharmacotherapy (2002)
- The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. Zamboni, W.C., Lüftner, D.I., Egorin, M.J., Schweigert, M., Sezer, O., Richter, T., Natale, J.J., Possinger, K. Ann. Oncol. (2001)
- Pharmacodynamic model of topotecan-induced time course of neutropenia. Zamboni, W.C., D'Argenio, D.Z., Stewart, C.F., MacVittie, T., Delauter, B.J., Farese, A.M., Potter, D.M., Kubat, N.M., Tubergen, D., Egorin, M.J. Clin. Cancer Res. (2001)
- Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. Zamboni, W.C., Egorin, M.J., Van Echo, D.A., Day, R.S., Meisenberg, B.R., Brooks, S.E., Doyle, L.A., Nemieboka, N.N., Dobson, J.M., Tait, N.S., Tkaczuk, K.H. J. Clin. Oncol. (2000)